TECH Stock Analysis — Bio-Techne
Sector: Healthcare
AI Verdict
Bio-Techne trades at 35.2x next year's earnings—expensive on sector norms, but justified if the 196.8% EPS growth materializes and its proprietary reagent moat keeps customers locked in.
Competitive Moat
Bio-Techne supplies essential reagents, antibodies, and instruments to life sciences and diagnostics labs, making it a critical supplier embedded in customers' research workflows. Its moat comes from proprietary reagents and deep integration into pharma R&D pipelines, which creates high switching costs for customers reliant on consistent quality and results.
Summary
Bio-Techne is on watch due to a forecasted 196.8% jump in earnings next year, compressing its forward P/E to 35.2x.
Where It Stands
Shares are up 31.94% over the past year with an RSI of 64.3 (near elevated territory) and trade at 35.2x forward earnings, which is slightly above the healthcare sector median of 22x.
Key Metrics
- RSI: 64.3 — Near Overbought
- Trailing P/E: 104.5x
- Forward P/E: 35.2x
- PEG Ratio: 0.53
- Earnings Growth: +2.0%
- Revenue Growth: +0.0%
- Market Cap: $11.2B
- Dividend Yield: 0.00%
- 1-Year Return: 31.94%
- 52-Week High: $72.36
- 52-Week Low: $43.20
Analyst Consensus
9 Buy · 13 Hold · 0 Sell (22 analysts)
Bull Case
Forward EPS is expected to surge 196.8%, making the 35.2x forward P/E look cheap for the growth on offer if the earnings ramp materializes.
Bear Case
If the forward P/E reverts to the sector median of 22x, the stock could see a 37% valuation drop even if earnings hit targets.
Catalyst to Watch
Watch for quarterly earnings reports to confirm whether the explosive EPS growth actually shows up in the numbers.